Vascular Biogenics (VBLT) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Vascular Biogenics (NASDAQ:VBLT) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.04), Fidelity Earnings reports.

VBLT stock opened at $2.20 on Friday. Vascular Biogenics has a 52 week low of $2.22 and a 52 week high of $2.22.

A number of hedge funds have recently added to or reduced their stakes in VBLT. IFP Advisors Inc boosted its holdings in Vascular Biogenics by 339.7% during the fourth quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 15,117 shares in the last quarter. Alps Advisors Inc. purchased a new stake in Vascular Biogenics during the fourth quarter worth about $234,000. ARK Investment Management LLC acquired a new position in Vascular Biogenics during the fourth quarter worth about $302,000. Finally, Raymond James & Associates raised its position in Vascular Biogenics by 71.5% during the fourth quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 23,124 shares during the last quarter. 5.49% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the stock. Zacks Investment Research raised shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Saturday, March 17th. ValuEngine raised shares of Vascular Biogenics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. JMP Securities downgraded shares of Vascular Biogenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 8th. Chardan Capital downgraded shares of Vascular Biogenics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $25.00 to $3.00 in a research report on Thursday, March 8th. Finally, Piper Jaffray downgraded shares of Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.19.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply